Amid breaking news of UK cabinet minister resignations, the Association of the British Pharmaceutical Industry has publicly welcomed the Brexit Draft Agreement.
The public response from the ABPI comes after the Brexit Secretary Dominic Raab and the Work and Pensions Secretary Esther McVey have resigned from the cabinet.
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI), has stated: “We welcome this important step towards securing a Brexit deal. Agreeing a transition period will mean that our members can continue to supply medicines to patients without delay or disruption come March 2019.”
The cabinet’s objections
Dominic Raab’s resignation letter outlined the following objections to Theresa May’s Brexit draft agreement:
“• The regulatory regime proposed for Northern Ireland presents a very real threat to the integrity of the United Kingdom
• I cannot support an indefinite backstop agreement, where the Eu holds a veto over our ability to exit
• I cannot reconcile the terms of the proposed deal with the promises we made to the country in our manifesto at the last election.”
While Thompson acknowledges further work to be done on the Brexit agreement, he commented that the Brexit draft agreement was an important step. He said: “There’s much to build on. But there’s more work to be done. We are committed to working with the UK and the EU so that close cooperation on scientific research and medicines regulation are central to a future partnership agreement for the benefit of all’.
A no-deal Brexit
The ABPI also said: “While significant contingency planning has been put in place by pharmaceutical companies to ensure that patients continue to get medicines in any Brexit scenario… this would be challenging in a ‘no deal’ scenario.”
Theresa May has stated in the House of Commons today that the government are still continuing to prepare for a no-deal scenario.